Key Drivers
- Zero revenue
- Severe cash burn
- Growing dilution
AIAI Summary
MANE has transitioned into a late‑stage, event‑driven bio play where valuation now hinges on the Phase 3 topline (H2 2026) and AAD data rather than fundamentals—monitor those readouts, near‑term cash runway post‑IPO, and any partnership announcements as the determinative catalysts. The key risk is binary clinical failure or the need for further dilutive financing if cash falls short, which would materially impair upside even if interim data sustain optimism.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Zero revenue
- •Severe cash burn
- •Growing dilution
MANE has no revenue, sustained large operating losses and severe cash burn that eroded cash from $53.1m to $5.7m and equity from -$48.5m to -$96.0m by 2025‑09‑30, leaving low reported leverage but high shareholder dilution and solvency risk.
Price Behavior
Key Price Behavior Insights:
- •Strong momentum
- •Defined support
- •Pullback risk
Price is decisively above its last month average (current $58.89 vs ~ $50.03), showing strong short‑term upward momentum from $52.80 into a $61.07 peak but with heightened volatility that risks a pullback toward $52–56 or the $45–49 support band.
Rapid mid‑March surge created short‑term volatility and increased pullback risk
Sentiment & News
Key News Insights:
- •Jefferies buy
- •AAD abstracts
- •Active outreach
Veradermics drew elevated analyst and investor attention in March 2026 on its oral hair‑loss program—driven by Jefferies' buy initiation, upcoming AAD data presentations, conference outreach, and a broadly positive analyst consensus signaling upside.
Continued clinical data releases and visible investor engagement should support sentiment and could materially re‑rate the stock if early readouts confirm differentiated efficacy
Similar Companies in Healthcare
Other companies in the same sector with AI ratings